Meningioma protein-protein interaction network

Archives of Iranian Medicine

Volumn 17, Issue 4, 2014, Pages 262-272

  Zali, Hakimeh ^a   Tavirani, Mostafa Rezaei ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biomarker; Hub; Meningioma; Protein complex; Protein protein interactions network

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE 6; FIBRONECTIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; MINICHROMOSOME MAINTENANCE PROTEIN 7; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; UBIQUITIN CONJUGATING ENZYME; CARRIER PROTEIN; CDC25A PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; DNA HELICASE; IFIT1 PROTEIN, HUMAN; IFIT3 PROTEIN, HUMAN; MCM2 PROTEIN, HUMAN; MCM7 PROTEIN, HUMAN; PROTEIN TYROSINE PHOSPHATASE; SEC31A PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION FACTOR S-II; TUMOR MARKER; UBE2E1 PROTEIN, HUMAN; VESICULAR TRANSPORT PROTEIN; XRCC5 PROTEIN, HUMAN;

ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; EXCISION REPAIR; GENE EXPRESSION; GENE ONTOLOGY; GENE OVEREXPRESSION; GENE REGULATORY NETWORK; HEMOSTASIS; HUMAN; MENINGIOMA; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS REGULATION; UNINDEXED SEQUENCE; UPREGULATION; DATA MINING; GENETICS; METABOLISM;

CARRIER PROTEINS; CDC25 PHOSPHATASES; CYCLIN-DEPENDENT KINASE 6; DATA MINING; DNA HELICASES; DOWN-REGULATION; GENE EXPRESSION; GENE ONTOLOGY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MENINGEAL NEOPLASMS; MENINGIOMA; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 2; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 7; PROTEIN INTERACTION MAPS; TRANSCRIPTIONAL ELONGATION FACTORS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-CONJUGATING ENZYMES; UP-REGULATION; VESICULAR TRANSPORT PROTEINS;

EID: 84899619191     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Elster AD, Challa VR, Gilbert TH, Richardson DN, Contento JC. Meningiomas: MR and histopathologic features. Radiology. 1989; 170: 857-862.
2. Filippi CG, Edgar MA, Ulug AM, Prowda JC, Heier LA, Zimmerman RD. Appearance of meningiomas on diffusion-weighted images: correlating diffusion constants with histopathologic findings.AJAR Am J Neuroradiol. 2001; 22: 65-72.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumor ofthe central nervous system. ActaNeuropathol. 2007; 114: 97-109.
4. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic menin-giomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986; 25: 233-242.
5. Barnholtz-Sloan JS, Kruchko C. Meningiomas: causes and risk factors. NeurosurgFocus. 2007; 23: E2.
6. Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E, et al. Meningioma. CritRev Oncol Hematol. 2008; 67: 153-171.
7. Longstreth WT Jr, Dennis LK, McGuire VM, Drangsholt MT, Ko-epsell TD. Epidemiology of intracranial Meningioma. Cancer. 1993; 72: 639-648.
8. Claus EB, Calvocoressi L, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M. Dental x-rays and risk of meningioma. Cancer. 2012; 118: 4530-4537.
9. Rabin BM, Meyer JR, Berlin JW, Marymount MH, Palka PS, Russell EJ. Radiation-induced changes in the central nervous system and head and neck. Radiographics. 1996; 16: 1055-1072.
10. Lee W, Chang KH, Choe G, Chi JG, Chung CK, Kim IH, et al. MR imaging features of clear-cell meningioma with diffuse leptomenin-geal seeding. AJNR Am J Neuroradiol. 2000; 21: 130-132.
11. Sanverdi SE, Ozgen B, Oguz KK, Mut M, Dolgun A, Soylemezoglu F, et al. Is diffusion-weighted imaging useful in grading and differentiating histopathological subtypes of meningiomas? Eur J Radiol. 2012; 81: 2389-2395.
12. Kleihues P, Cavenee WK.WorldHealth Organization Classification of Tumours. Pathology and genetics of tumours ofthe nervous system. 2th ed. Lyon: IARC Press; 2000.
13. Bello MJ, Aminoso C, Lopez-Marin I, Arjona D, Gonzalez- Gomez P, Alonso ME, et al. DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol (Berl). 2004; 108: 413-421.
14. Liu Y, Pang JC, Dong S, Mao B, Poon WS, Ng HK. Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol. 2005; 36: 416-425.
15. Lekanne Deprez RH, Riegman PH, Groen NA, Warringa UL, van Biezen NA, Molijn AC, et al. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced trans-location in a meningioma. Oncogene. 1995; 10: 1521-1528.
16. Staal FJ, van der Luijt RB, Baert MR, van Drunen J, van Bakel H, Peters E, et al. A novel germline mutation of PTEN associated with brain tumor of multiple lineages. Br J Cancer. 2002; 86: 1586-1591.
17. Zattara-Cannoni H, Roll P, Figarella-Branger D, Lena G, Dufour H, Grisoli F, et al. Cytogenetic study of six cases of radiation-induced meningiomas. Cancer Genet Cytogenet. 2001; 126: 81-84.
18. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013; 45: 285-289.
19. Sadetzki S, Flint-Richter P, Starinsky S, Novikov I, Lerman Y, Goldman B, et al. Genotyping of patients with sporadic and radiation- associated meningiomas. Cancer Epidemiol Biomarkers Prev. 2005; 14: 969-976.
20. Saydam O, Senol O, Schaaij-Visser T, Pham TV, Piersma SR, Stem-mer-Rachamimov AO, et al. Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. J Proteome Res. 2010; 9: 485-494.
21. Tummalapalli P, Gondi CS, Dinh DH, Gujrati M, Rao JS. RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-Lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. Int J Oncol. 2007; 31: 5-17.
22. Martinez-Glez V, Franco-Hernandez C, Alvarez L, De Campos JM, Isla A, Vaquero J, et al. Meningiomas and schwannomas: molecular subgroup classification found by expression arrays. Int J Oncol. 2009; 34: 493-504.
23. Okamoto H, Li J, Vortmeyer AO, Jaffe H, Lee YS, Glasker S, et al. Comparative proteomic profiles of meningioma subtypes. Cancer Res. 2006; 66: 10199-10204.
24. Baines AJ, Lu HC, Bennett PM. The Protein 4.1 family: Hub proteins in animals for organizing membrane proteins. Biochim Biophys Acta. 2014; 1838: 605-619.
25. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, et al. Gene expression profiling of ErbB receptors and ligands in human meningiomas. Cancer Invest. 2009; 27: 691-698.
26. Das A, Tan WL, Smith DR. p53 point mutation is rare in meningiomas from Singaporean patients. Asian J Surg. 2005; 28: 7-10.
27. Siddique K, Yanamandra N, Gujrati M, Dinh D, Rao JS, Olivero W. Expression of matrix metalloproteinases, their inhibitors, and uro-kinase plasminogen activator in human meningiomas. Int J Oncol. 2003; 22: 289-294.
28. Mawrin C, Sasse T, Kirches E, Kropf S, Schneider T, Grimm C, et al. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human menin-giomas. Clin Cancer Res. 2005; 11: 4074-4082.
29. Watson MA, Gutmann DH, Peterson K, Chicoine MR, Kleinschmidt-DeMasters BK, Brown HG, et al. Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays. Am JPathol. 2002; 161: 665-672.
30. Wrobel G, Roerig P, Kokocinski F, Neben K, Hahn M, Reifenberger G, et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer. 2005; 114: 249-256.
31. Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, et al. Identification ofthe deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery. 2008; 63: 771-780.
32. Arnold SA, Brekken RA. SPARC: a matricellular regulator of tumori-genesis. J Cell Commun Signal. 2009; 3: 255-273.
33. Murphy M, Pykett MJ, Harnish P, Zang KD, George DL. Identification and characterization of genes differentially expressed in menin-giomas. Cell Growth Differ. 1993; 4: 715-722.
34. Aruga J, Nozaki Y, Hatayama M, Odaka YS, Yokota A. Expression of ZIC family genes in meningiomas and other brain tumors. BMC Cancer. 2010; 10: 79.
35. Laurendeau I, Ferrer M, Garrido D, D'Haene N, Ciavarelli P, Basso A, et al. Gene expression profiling ofthe hedgehog signaling pathway in human meningiomas. MolMed. 2010; 16: 262-270.
36. Terzia A, Saglama A, Barak A, Soylemezoglu F. The significance of immunohistochemical expression of Ki-67, p53, p21, and p16 in me-ningiomas tissue arrays. Pathol Res Pract. 2008; 204: 305-314.
37. MartInez-Gleza V, Alvareza L, Franco-Hernandeza C, Torres-Martina M, de Camposb JM, Islac A, et al. Genomic deletions at 1p and 14q are associated with an abnormal cDNA microarray gene expression pattern in meningiomas but not in schwannomas. Cancer Genet Cyto-genet. 2010; 196: 1-6.
38. von Randowa AJ, Schindlerc S, Tews DS. Expression of extracellular matrix-degrading proteins in classic, atypical, and anaplastic menin-giomas. Pathol Res Pract. 2006; 202: 365-372.
39. Di Vinci A, Brigati C, Casciano I, Banelli B, Borzi L, Forlani A, et al. HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. TranslRes. 2012; 160: 355-362.
40. Piaskowski S, Rieske P, Szybka M, Wozniak K, Bednarek A, Pluciennik E, et al. GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet Cytogenet. 2005; 162: 63-67.
41. Muller P, Henn W, Niedermayer I, Ketter R, Feiden W, Steudel WI, et al. Deletion of chromosome 1p and loss of expression of alkaline phosphatase indicate progression of meningiomas. Clin Cancer Res. 1999; 5: 3569-3577.
42. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet. 2000; 9: 1495-1500.
43. Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH. Identification of a third Protein 4.1 tumor suppressor, Protein 4.1R in meningioma pathogenesis. NeurobiolDis. 2003; 13: 191-202.
44. Real-Chicharro A, Ruiz-Mostazo I, Navas-Delgado I, Kerzazi A, Chniber O, Sanchez-Jimenez F, et al. Protopia: a protein-protein interaction tool. BMCBioinformatics. 2009; 10: S17.
45. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of bio-molecular interaction networks. Genome Res. 2003; 13: 2498-2504.
46. Bader JD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinfor-matics. 2003; 4: 2.
47. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology annotation networks. Bioinformatics. 2009; 25: 1091-1093.
48. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. MolBiol Cell. 2002; 13: 1977-2000.
49. Ficenec D, Osborne M, Pradines J, Richards D, Felciano R, Cho RJ, et al. Computational knowledge integration in biopharmaceutical research. Brief Bioinform. 2003; 4: 260-278.
50. Bergmann S, Ihmels J, Barkai N. Similarities and differences in genome-wide expression data of six organisms. PLoSBiol. 2004; 2: E9.
51. Stuart JM, Segal E, Koller D, Kim SK. A genecoexpression network for global discovery of conserved genetic modules. Science. 2003; 302: 249-255.
52. Meyerson M, Harlow E. Identification of Gl kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994; 14: 2077-2086.
53. Fiaschi-Taesch NM, Salim F, Kleinberger J, Troxell R, Cozar-Castel-lano I, Selk K, et al. Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes. 2010; 59: 1926-1936.
54. David Y, Ziv T, Admon A, Navon A. The E2 ubiquitin-conjugating enzymes direct polyubiquitination to preferred lysines. J Biol Chem. 2010; 285: 8595-8604.
55. Tuteja N, Tuteja R, Ochem A, Taneja P, Huang NW, Simoncsits A, et al. Human DNA helicase II: a novel DNA unwinding enzyme identified as the Ku autoantigen. EMBO J. 1994; 13: 4991-5001.
56. Oderwald H, Hughes MJ, Jost JP. Non-histone protein 1 (NHP1) is a member of the Ku protein family which is upregulated in diferentiat-ing mouse myoblasts and human promyelocytes. FEBS Lett. 1996; 382: 313-318.
57. Todorov IT, Pepperkok R, Philipova RN, Kearsey SE, An-sorge W, Werner D. A human nuclear protein with sequence homology to a family of early S phase proteins is required for entry into S phase and for cell division. J Cell Sci. 1994; 107: 253-265.
58. Xiao S, Li D, Zhu HQ, Song MG, Pan XR Jia PM, et al. RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci USA. 2006; 103: 16448-16453.
59. Huang X, Shen N, Bao C, Gu Y, Wu L, Chen S. Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells. Arthritis Res Ther. 2008; 10: R91.
60. Killcoyne S, Carter GW, Smith J, Boyle J. Cytoscape: a community-based framework for network modeling. Methods Mol Biol. 2009; 563: 219-239.
61. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44-57.
62. Cojocaru M, Bouchard A, Cloutier P, Cooper JJ, Varza-vand K, Price DH, et al. Transcription factor IIS cooperates with the E3 ligase UBR5 to ubiquitinate the CDK9 subunit of the positive transcription elongation factor B. J Biol Chem. 2011; 286: 5012-5022.
63. Yoshioka H, Hama S, Taniguchi E, Sugiyama K, Arita K, Kurisu K. Peritumoral brain edema associated with meningioma: influence of vascular endothelial growth factor expression and vascular blood supply. Cancer. 1999; 85: 936-944.
64. Christov C, Lechapt-Zalcman E, Adle-Biassette H, Nachev S, Gherar-di RK. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptor flt-1 in microcystic meningiomas.Acta Neuropathol (Berl). 1999; 98: 414-420.
65. Tang BL, Zhang T, Low DYH, Wong ET, Horstmann H, Hong W. Mammalian homologues of yeast sec31p. An ubiquitously expressed form is localized to endoplasmic reticu-lum (ER) exit sites and is essential for ER-Golgi transport. J Biol Chem. 2000; 275: 13597-13604.
66. Falck J, Mailand N, Syljuaasen RG, Bartek J, Lukas J. the ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature. 2001; 410: 842-847.
67. Terenzi F, Saikia P, Sen GC. Interferon-inducible protein, P56, inhib- its HPV DNA replication by binding to the viral protein E1. EMBO J. 2008; 27: 3311-3321.
68. Li Y, Li C, Xue P, Zhong B, Mao AP, Ran Y, et al. ISG56 is a negative-feedback regulator of virus-triggered signaling and cellular antiviral response. Proc Natl Acad Sci USA. 2009; 106: 7945-7950.
69. Wang JL, Nister M, Hermansson M, Westermark B, Ponten J. Expression of PDGF beta-receptors in human meningioma cells. Int J Cancer. 1990; 46: 772-778.
70. Johnson MD, Woodard A, Kim P, Frexes-Steed M. Evidence for mito-gen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells. JNeurosurg. 2001; 94: 293-300.
71. Johnson M, Toms S. Mitogenic signal transduction pathways in me-ningiomas: novel targets for meningioma chemotherapy? J Neuro-patholExp Neurol. 2005; 64: 1029-1036.
72. Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS. Evidence for phosphatidylinositol 3-kinase-Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. J Neurosurg. 2002; 97: 668-675.